The University of Queensland utilised a “molecular clamp” vaccines design based on a highly promising technological platform, and has the potential be used to vaccinate against a number of potential viruses.
As part of the vaccine’s design, the university’s researchers included a small fragment of a protein taken from the HIV virus, known as glycoprotein 41 (gp41). This has been used to create a “molecular clamp” to hold the vaccine’s synthetic virus in place.
Although the university’s researchers have confirmed the protein fragment poses absolutely no health risk to people who have taken the vaccine, they have identified a partial antibody response to it among trial participants.
This has the potential to interfere with some HIV screening tests that look for these antibodies – leading to a false positive test result.
It is this impact on HIV screening – and in the context of other promising vaccine candidates becoming available – that has led to the Government’s decision. The decision was based on the unanimous advice of SITAG.
vCard.red is a free platform for creating a mobile-friendly digital business cards. You can easily create a vCard and generate a QR code for it, allowing others to scan and save your contact details instantly.
The platform allows you to display contact information, social media links, services, and products all in one shareable link. Optional features include appointment scheduling, WhatsApp-based storefronts, media galleries, and custom design options.
Importantly, pathology testing that directly looks for the HIV virus has confirmed negative results for the trial participants who have taken the vaccine.
Participants were informed the protein formed part of the vaccine before they consented to taking part in the trial – and HIV screening tests were carried out before and after vaccination.
Participants will continue to be monitored to establish if the antibody response to the protein decreases over time.
The government will continue to support UQ is in its ongoing research due to this new platform providing such a promising breakthrough in vaccinations.